Michael F X Gnant

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. ncbi A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer
    Klaus Sahora
    MD FACS, Department of Surgery and Comprehensive Cancer Center Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Anticancer Res 34:2377-84. 2014
  2. pmc Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial
    G Pfeiler
    Division of Gynecology and Gynecological Oncology, Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
    Br J Cancer 108:1408-14. 2013
  3. pmc The evolving role of zoledronic acid in early breast cancer
    Michael Gnant
    Department of Surgery, Medical University of Vienna, Vienna, Austria
    Onco Targets Ther 2:95-104. 2009
  4. doi Role of bisphosphonates in postmenopausal women with breast cancer
    Michael Gnant
    Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Austria Electronic address
    Cancer Treat Rev 40:476-84. 2014
  5. pmc The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial
    M Gnant
    Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
    Br J Cancer 109:589-96. 2013
  6. doi Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2
    Michael Gnant
    Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    J Natl Cancer Inst 105:654-63. 2013
  7. doi Adjuvant bisphosphonates: a new standard of care?
    Michael Gnant
    Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
    Curr Opin Oncol 24:635-42. 2012
  8. doi The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer
    Michael Gnant
    Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Wien, Waehringer Guertel, Vienna, Austria
    Curr Oncol Rep 15:14-23. 2013
  9. doi Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition
    Michael Gnant
    Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, A 1090 Wien, Waehringer Guertel 18 20, Austria
    Expert Rev Anticancer Ther 12:1579-89. 2012
  10. doi Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature
    Michael Gnant
    Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Cancer Treat Rev 38:407-15. 2012

Detail Information

Publications74

  1. ncbi A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer
    Klaus Sahora
    MD FACS, Department of Surgery and Comprehensive Cancer Center Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Anticancer Res 34:2377-84. 2014
    ..We report the results of a phase II trial of adding the anti-ascular endothelial growth factor (VEGF) bevacizumab to gemcitabine neoadjuvant chemotherapy for patients with borderline and unresectable non-metastatic pancreatic cancer...
  2. pmc Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial
    G Pfeiler
    Division of Gynecology and Gynecological Oncology, Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
    Br J Cancer 108:1408-14. 2013
    ..We investigated the impact of BMI on the efficacy of single tamoxifen and tamoxifen plus an aromatase inhibitor in the well-defined prospective study population of the ABCSG-06 trial...
  3. pmc The evolving role of zoledronic acid in early breast cancer
    Michael Gnant
    Department of Surgery, Medical University of Vienna, Vienna, Austria
    Onco Targets Ther 2:95-104. 2009
    ..The results of these zoledronic acid trials will be reviewed herein, and evidence supporting the antitumor effects of adjuvant zoledronic acid will be discussed...
  4. doi Role of bisphosphonates in postmenopausal women with breast cancer
    Michael Gnant
    Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Austria Electronic address
    Cancer Treat Rev 40:476-84. 2014
    ..This review addresses these controversies in the context of translational research, which may provide the rationale for ongoing studies and evolving treatment paradigms in this area. ..
  5. pmc The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial
    M Gnant
    Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
    Br J Cancer 109:589-96. 2013
    ..We investigated whether body mass index (BMI) can be used as a predictive parameter indicating patients who benefit from extended aromatase inhibitor (AI) treatment...
  6. doi Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2
    Michael Gnant
    Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    J Natl Cancer Inst 105:654-63. 2013
    ..Exploratory analyses in BOLERO-2 evaluated the effect of everolimus on bone marker levels and progressive disease in bone...
  7. doi Adjuvant bisphosphonates: a new standard of care?
    Michael Gnant
    Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
    Curr Opin Oncol 24:635-42. 2012
    ..This review evaluates the recent clinical evidence for the effectiveness of adjuvant bisphosphonate therapy in breast cancer...
  8. doi The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer
    Michael Gnant
    Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Wien, Waehringer Guertel, Vienna, Austria
    Curr Oncol Rep 15:14-23. 2013
    ..This review will focus on the current ET options for women with HR(+) ABC who have progressed on prior AI therapy, the role of mTOR-mediated signaling in breast cancer, and the clinical evidence supporting the use of mTOR inhibitors...
  9. doi Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition
    Michael Gnant
    Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, A 1090 Wien, Waehringer Guertel 18 20, Austria
    Expert Rev Anticancer Ther 12:1579-89. 2012
    ..This article reviews the current data from studies of mTOR inhibitors everolimus and temsirolimus in combination with endocrine therapies to overcome treatment resistance in patients with advanced breast cancer...
  10. doi Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature
    Michael Gnant
    Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Cancer Treat Rev 38:407-15. 2012
    ..Ongoing studies will provide further insight regarding the anticancer potential of bisphosphonates and other antiresorptive agents...
  11. ncbi Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts
    Michael Gnant
    Medical University of Vienna, Vienna, Austria
    Breast Dis 33:71-81. 2011
    ..Although it is too early to determine which patients are most likely to benefit from the anticancer potential of bisphosphonates, future research will help further guide therapy in this setting...
  12. doi Bisphosphonates: prevention of bone metastases in lung cancer
    Lynn Decoster
    Department of Pulmonology, University Hospital Gasthuisberg, Leuven, Belgium
    Recent Results Cancer Res 192:93-108. 2012
    ..Other bone-targeted therapies are being investigated in phase II and III clinical trials and might expand the therapeutic arsenal in the near future...
  13. ncbi Anticancer activity of bisphosphonates in breast cancer
    Michael Gnant
    Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
    Anticancer Agents Med Chem 12:114-22. 2012
    ..Furthermore, the use of zoledronic acid to reduce the risk of recurrence is emerging based on ongoing clinical research...
  14. doi Bisphosphonates: prevention of bone metastases in breast cancer
    Michael Gnant
    Department of Surgery, Medical University of Vienna, Wien, Austria
    Recent Results Cancer Res 192:65-91. 2012
    ....
  15. pmc Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
    Rupert Bartsch
    Department of Medicine 1 and Cancer Centre, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria
    BMC Cancer 9:367. 2009
    ..Others however remain candidates for continued antibody treatment (treatment beyond progression). Here, we aimed to identify factors predicting for activity of second-line trastuzumab-based therapy...
  16. doi Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
    Michael Gnant
    Department of Surgery, Comprehensive Cancer Centre Vienna, Medical University of Vienna, A 1090 Vienna, Austria
    Lancet Oncol 12:631-41. 2011
    ..We have now assessed long-term clinical efficacy including disease-free survival and disease outcomes in patients receiving anastrozole or tamoxifen with or without zoledronic acid...
  17. ncbi Management of bone loss induced by aromatase inhibitors
    Michael Gnant
    Department of Surgery Medical, University of Vienna, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria
    Cancer Invest 24:328-30. 2006
    ..As increase in fracture incidence have already been reported in most major trials of aromatase inhibitors. Bisphosphonates are used to treat this cancer-treatment induced bone loss, the available data is reviewed here...
  18. doi Endocrine therapy plus zoledronic acid in premenopausal breast cancer
    Michael Gnant
    Medical University of Vienna, Austria
    N Engl J Med 360:679-91. 2009
    ..Aromatase inhibitors are superior to tamoxifen in postmenopausal patients, and preclinical data suggest that zoledronic acid has antitumor properties...
  19. pmc Prevention of bone metastases and management of bone health in early breast cancer
    Michael Gnant
    Department of Surgery, Medical University of Vienna, Vienna, Austria
    Breast Cancer Res 12:216. 2010
    ..In addition, bisphosphonates maintain bone health during adjuvant therapy; this may be especially important for women who are at high risk for fracture...
  20. ncbi Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group
    Michael F X Gnant
    Department of Surgery, General Hospital, Medical University of Vienna, Vienna, Austria
    J Clin Oncol 25:820-8. 2007
    ..This study examined whether zoledronic acid can prevent bone loss associated with adjuvant endocrine therapy in premenopausal patients...
  21. ncbi Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials
    M Gnant
    Department of Surgery, Medical University of Vienna, Vienna, Austria
    Curr Cancer Drug Targets 9:824-33. 2009
    ..Results from these studies are likely to expand the role of bisphosphonates, especially zoledronic acid, in the adjuvant therapy setting...
  22. doi Zoledronic acid in the treatment of early-stage breast cancer: is there a final verdict?
    Michael Gnant
    Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090, Vienna, Austria
    Curr Oncol Rep 14:35-43. 2012
    ..Together, these data support a potential role for zoledronic acid beyond bone health in breast cancer and suggest that the endocrine environment may influence the anticancer potential of zoledronic acid...
  23. ncbi Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
    Michael Gnant
    Department of Surgery, Medical University of Vienna, Vienna, Austria
    Clin Breast Cancer 9:S18-27. 2009
    ..Results from ongoing studies are expected to further elucidate the benefits of bisphosphonates in maintaining bone health and improving clinical outcomes in patients with breast cancer...
  24. doi [Neoadjuvant treatment and breast conserving surgery - a success of clinical research in breast cancer]
    Michael Gnant
    Austrian Breast and Colorectal Cancer Study Group, Universitatsklinik fur Chirurgie, Medizinische Universität Wien, Wien, Osterreich
    Wien Med Wochenschr 160:163-6. 2010
    ..The trials of the ABCSG, particularly those dealing with neoadjuvant therapy, were instrumental in this development...
  25. doi Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy
    Martin Filipits
    Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, A 1090 Vienna, Austria
    Clin Cancer Res 15:5888-94. 2009
    ..The purpose of the present study was to assess the clinical relevance of p27 expression in postmenopausal hormone receptor-positive breast cancer patients who were treated with adjuvant tamoxifen therapy...
  26. doi Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
    Michael Gnant
    Department of Surgery, Medical University of Vienna, General Hospital Vienna, Vienna, Austria
    Lancet Oncol 9:840-9. 2008
    ..The aim of this substudy is to gain insight into bone health in this setting...
  27. ncbi Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breas
    Raimund Jakesz
    Department of Surgery, Vienna University, Vienna General Hospital, Austria
    J Clin Oncol 20:4621-7. 2002
    ..The purpose of Austrian Breast and Colorectal Cancer Study Group Trial 5 was to compare the efficacy of a combination endocrine treatment with standard chemotherapy...
  28. ncbi Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer
    Susanne Taucher
    Department of Surgery, Vienna University Medical School, Vienna, Austria
    Wien Klin Wochenschr 116:26-31. 2004
    ..Since core needle biopsy is increasingly used for the diagnosis of breast cancer, the purpose of this study was to assess the reliability of HER2/neu evaluation using this technique in patients with primary breast cancer...
  29. ncbi Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer
    Rupert Bartsch
    First Department of Medicine and Cancer Centre, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria
    J Clin Oncol 25:3853-8. 2007
    ..We evaluated the efficacy and tolerability of capecitabine plus trastuzumab after anthracycline and docetaxel or vinorelbine failure and prior trastuzumab exposure...
  30. doi Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy
    Margaretha Rudas
    Department of Pathology, Medical University of Vienna, Austria
    Clin Cancer Res 14:1767-74. 2008
    ..The objective of our study was to determine the clinical relevance of cyclin D1 expression in hormone receptor-positive breast cancer patients who were treated with tamoxifen-based therapy...
  31. ncbi Do we need HER-2/neu testing for all patients with primary breast carcinoma?
    Susanne Taucher
    Department of Surgery, Vienna University Medical School, Vienna, Austria
    Cancer 98:2547-53. 2003
    ..The objective of the current study was to investigate the probability, calculated using parameters that are assessed routinely in clinical practice, that patients with breast carcinoma had positive HER-2/neu status...
  32. ncbi Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer
    Sebastian F Schoppmann
    Department of Surgery, University of Vienna, Vienna, Austria
    Int J Cancer 104:677-82. 2003
    ..Our results also suggest that due to the apparent interaction of Id-1 with the steroid-receptor system in breast cancer, hormonal therapies might influence Id-1 expression and its impact on clinical outcome...
  33. ncbi Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment
    Rupert Bartsch
    First Department of Medicine, Medical University of Vienna, Vienna, Austria
    Clin Cancer Res 13:4435-9. 2007
    ..In this study, we evaluated factors that are potentially predictive of response and time to progression in patients treated with fulvestrant...
  34. ncbi Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer
    Monika Schindl
    Institute of Clinical Pathology, Department of Surgery, University of Vienna Medical School, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Clin Cancer Res 8:1831-7. 2002
    ..The aim of this study was to determine the prognostic influence of HIF-1alpha expression in patients with advanced-stage breast cancer, evident by positive lymph nodes...
  35. ncbi In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells
    Anton Stift
    Department of Surgery, University of Vienna Medical School, A 1090 Vienna, Austria
    Int J Oncol 22:651-6. 2003
    ..Even though this study was confined to a single patient, the data might open a door for novel immunotherapeutical strategies...
  36. ncbi Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer
    Peter C Dubsky
    Department of General Surgery, University of Vienna, Austria
    Clin Breast Cancer 3:65-72. 2002
    ..Future studies should focus on unveiling the young age surrogate in order to improve treatment and prognosis...
  37. ncbi Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer
    Susanne Taucher
    Department of Surgery, Vienna University Medical School, Vienna, Austria
    Breast Cancer Res Treat 82:207-13. 2003
    ....
  38. pmc Significant increase in breast conservation in 16 years of trials conducted by the Austrian Breast & Colorectal Cancer Study Group
    Raimund Jakesz
    Department of Surgery, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Surg 237:556-64. 2003
    ..To confirm evidence that breast-conserving treatment (BCT) does not impair the prognosis in breast cancer patients as compared to mastectomy and to argue that it be regarded as the treatment of choice in stage I and II disease...
  39. ncbi Dendritic cell vaccination in medullary thyroid carcinoma
    Anton Stift
    Department of Surgery, University of Vienna, Medical School, Vienna, Austria
    Clin Cancer Res 10:2944-53. 2004
    ..Palliative treatment options show no significant benefit. A promising treatment approach for human cancer is based on the vaccination of autologous dendritic cells (DCs)...
  40. ncbi Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor
    Catharina Wenzel
    Department of Internal Medicine I, Division of Oncology, University Hospital of Vienna, 1090 Vienna, Austria
    Anticancer Drugs 13:67-74. 2002
    ..Thus, this regimen can be considered for further clinical trials...
  41. ncbi Overexpression of the human homologue for Caenorhabditis elegans cul-4 gene is associated with poor outcome in node-negative breast cancer
    Monika Schindl
    Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
    Anticancer Res 27:949-52. 2007
    ..The aim of this study was to investigate the expression and prognostic relevance of CUL-4 protein in lymph node-negative breast cancer, one of the most common malignancies worldwide...
  42. doi Breast cancer chemoprevention - a vision not yet realized
    P Blaha
    Department of Surgery, Medical University of Vienna, Vienna General Hospital, Vienna, Austria
    Eur J Cancer Care (Engl) 18:438-46. 2009
    ..With promising results in adjuvant settings, aromatase inhibitors may deliver better prevention treatment options in the future, nevertheless, more research is needed to reliably predict risk on an individual basis in the future...
  43. ncbi Cryopreservation of monocytes is superior to cryopreservation of immature or semi-mature dendritic cells for dendritic cell-based immunotherapy
    Hubert Hayden
    Department of Surgery, Medical University of Vienna, Vienna, Austria
    J Immunother 32:638-54. 2009
    ..These findings may further improve DC-based immunotherapeutical protocols. Cryopreservation of unchallenged monocytes enables targeted therapy by loading DC with varying antigenic compositions in case of tumor escape during treatment...
  44. ncbi Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma
    Thomas Bachleitner-Hofmann
    Department of Surgery, Medical University of Vienna, A 1090 Vienna, Austria
    Oncol Rep 21:1585-92. 2009
    ..Combined treatment with different tumor cell lysate-pulsed DCs increases the likelihood of a calcitonin tumor marker response and should therefore be preferred over monotherapy with DCs pulsed with a single lysate...
  45. ncbi Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation?
    Herwig Pokorny
    University Hospital of Vienna, Department of Transplant Surgery, Vienna, Austria
    Am J Transplant 5:788-94. 2005
    ..Doxorubicin chemotherapy did not improve organ survival and disease-free survival in patients undergoing liver transplantation for HCCA...
  46. doi The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer
    Rupert Bartsch
    First Department of Medicine and Cancer Centre, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18 20, Vienna 1090, Austria
    Breast Cancer Res Treat 115:373-80. 2009
    ..Endocrine therapy is the preferred treatment in oestrogen- and/or progesterone-receptor (ER/PgR) positive breast cancer. Fulvestrant is a pure ER-antagonist. We present results from the Austrian Fulvestrant Registry...
  47. ncbi Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells
    Christian F Singer
    Department of Obstetrics, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Endocr Relat Cancer 16:73-83. 2009
    ..We hypothesize that receptor phosphorylation is caused by growth factor stimulation in response to intraoperative tissue damage, and perioperative inhibition of specific cytokines could become a promising therapeutic strategy...
  48. ncbi Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy
    Christine Brostjan
    Department of General Surgery, General Hospital, University of Vienna, Vienna, Austria
    Cancer 98:2291-301. 2003
    ....
  49. ncbi Heat shock treatment of tumor lysate-pulsed dendritic cells enhances their capacity to elicit antitumor T cell responses against medullary thyroid carcinoma
    Thomas Bachleitner-Hofmann
    Department of Surgery, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    J Clin Endocrinol Metab 91:4571-7. 2006
    ..The aim of our investigations was to evaluate whether heat shock also increases the capacity of human monocyte-derived DCs to stimulate antitumor T cell responses against MTC tumor cells...
  50. ncbi VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival
    Sebastian F Schoppmann
    Department of Surgery, University of Vienna, Austria
    Surgery 139:839-46. 2006
    ..Aim of this study was to clear the role of VEGF-C/D expressing TAMs in invasive breast cancer...
  51. ncbi Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer
    Sebastian F Schoppmann
    Department of Surgery, University of Vienna, Waehringer, Vienna, Austria
    Breast Cancer Res Treat 99:135-41. 2006
    ....
  52. ncbi Preoperative core needle biopsy does not increase local recurrence rate in breast cancer patients
    Florian Fitzal
    Department of Surgery, General Hospital, University Vienna, Waehringer Guertd 18 20, 1090 Vienna, Austria
    Breast Cancer Res Treat 97:9-15. 2006
    ..The impact of this observation on local recurrence and overall survival rate is, however, not fully investigated...
  53. pmc Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer
    Sebastian F Schoppmann
    Department of Surgery, Medical University of Vienna, Austria
    Ann Surg 240:306-12. 2004
    ..The aim of this study was to investigate the prognostic relevance of lymphangiogenesis and lymphovascular invasion in a large cohort of breast cancer patients...
  54. ncbi Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
    Raimund Jakesz
    Austrian Breast and Colorectal Cancer Study Group ABCSG, Vienna Medical University, Vienna General Hospital, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Lancet 366:455-62. 2005
    ..We investigate whether women who have received a period of adjuvant tamoxifen would benefit from being switched to anastrozole...
  55. ncbi Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF
    Catharina Wenzel
    Department of Internal Medicine I, Division of Clinical Oncology, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Breast Cancer Res Treat 104:109-14. 2007
    ..We questioned the impact of histologic type invasive ductal carcinoma (IDC) versus invasive lobular carcinoma (ILC) on response to primary chemotherapy...
  56. ncbi Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer
    Richard Potter
    Department of Surgery, Medical University of Vienna, Vienna, Austria
    Int J Radiat Oncol Biol Phys 68:334-40. 2007
    ..In women with favorable early breast cancer treated by lumpectomy plus tamoxifen or anastrazole, it remains unclear whether whole breast radiotherapy is beneficial...
  57. ncbi Breast-conserving surgery for T3/T4 breast cancer: an analysis of 196 patients
    Florian Fitzal
    Department of Surgery, Medical University Vienna, Waehringer Guertel 18 20, 1080 Vienna, Austria
    Breast Cancer Res Treat 103:45-52. 2007
    ..In special cancer centers up to 90% of patients are treated with BCT. T3/T4 breast cancer is one of the few contraindications for BCT. However, retrospective data suggest that BCT may be eligible in selected cases of T3/T4 breast cancer...
  58. ncbi Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen
    Thomas Bachleitner-Hofmann
    Department of Surgery, University of Vienna, A 1090 Vienna, Austria
    Clin Cancer Res 8:3427-32. 2002
    ....
  59. doi Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy
    Peter Dubsky
    Department of Surgery, Medical University Vienna, Vienna, Austria
    Clin Cancer Res 14:2082-7. 2008
    ....
  60. doi Breast-conserving therapy for centrally located breast cancer
    Florian Fitzal
    Department of Surgery, Medical University of Vienna, Austria
    Ann Surg 247:470-6. 2008
    ..To analyze whether breast-conserving therapy (BCT) may be an oncologically safe approach and result in a good cosmesis in patients with centrally located breast cancer (CLBC)...
  61. ncbi Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer
    Rupert Bartsch
    First Department of Medicine and Cancer Centre, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Cancer Chemother Pharmacol 62:903-10. 2008
    ..In this trial, we evaluated the efficacy and safety of gemcitabine and trastuzumab after earlier exposure to anthracyclines, docetaxel and/or vinorelbine, and trastuzumab...
  62. ncbi Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a
    Raimund Jakesz
    Department of Surgery, Vienna Medical University, Vienna General Hospital, Waehringer Guertel 18 20, Vienna A 1090, Austria
    J Natl Cancer Inst 99:1845-53. 2007
    ..We examined the efficacy and tolerability of extended adjuvant therapy with another aromatase inhibitor, anastrozole, for 3 years among women who had completed 5 years of adjuvant therapy...
  63. ncbi Allogeneic tumor lysate can serve as both antigen source and protein supplementation for dendritic cell culture
    Peter Dubsky
    Department of Surgery, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Cancer Immunol Immunother 57:859-70. 2008
    ..We addressed the question whether protein supplementation can be omitted in the presence of allogeneic tumor lysate...
  64. ncbi Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14
    Günther G Steger
    Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
    J Clin Oncol 25:2012-8. 2007
    ..This phase III trial evaluated whether doubling the number of cycles of neoadjuvant treatment increased the pCR rate...
  65. doi Low telomerase activity: possible role in the progression of human medullary thyroid carcinoma
    Guido Stadler
    Institute of Applied Microbiology, Department of Biotechnology, University of Natural Resources and Applied Life Sciences, Vienna, Austria
    Eur J Cancer 44:866-75. 2008
    ....
  66. ncbi Impact of pretreatment thrombocytosis on survival in primary breast cancer
    Susanne Taucher
    Department of Surgery, University of Vienna Medical School, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Thromb Haemost 89:1098-106. 2003
    ..1355). In our retrospective study, elevated platelet counts at time of diagnosis were associated with poor prognosis in breast cancer. We hypothesize that platelets may contribute to the pathophysiology of hematogenous metastasis...
  67. ncbi Inosine 5'-monophosphate dehydrogenase inhibition by mycophenolic acid impairs maturation and function of dendritic cells
    Peter C Dubsky
    Vienna Medical School, Department of Surgery, A 1090 Wien, Wahringer Gurtel 18 20, Austria
    Clin Chim Acta 364:139-47. 2006
    ..Recent evidence suggests MPA to affect antigen-presenting cells...
  68. ncbi Preventive mastectomy in patients at breast cancer risk due to genetic alterations in the BRCA1 and BRCA2 gene
    Susanne Taucher
    Department of Surgery, Medical School, Vienna University, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Langenbecks Arch Surg 388:3-8. 2003
    ..The availability of genetic testing for inherited mutations in the BRCA1 and BRCA2 gene provides potentially valuable information to women at high risk of breast and ovarian cancer...
  69. ncbi Breast conservation: evolution of surgical strategies
    Florian Fitzal
    Department of Surgery, Medical University of Vienna, Vienna, Austria
    Breast J 12:S165-73. 2006
    ..However, several specific factors must be considered to choose the correct surgical strategy. This review provides a scientific overview of the history, surgical methodology, and specific aspects of BCT...
  70. doi Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial
    Georg Pfeiler
    Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Waehringer Guertel 18 20, A 1090, Vienna, Austria
    J Clin Oncol 29:2653-9. 2011
    ....
  71. ncbi Gastrointestinal autonomic nerve tumors: a surgical point of view
    Anton Stift
    Department of General Surgery, Medical University of Vienna, Waehringerguertel 18 20, A 1090 Vienna, Austria
    World J Gastroenterol 10:2447-51. 2004
    ..We report two cases and performed an analysis of the literature by comparing our findings with the available case reports in the medical literature...
  72. ncbi Retroviral targeting of proliferating endothelial cells
    Alexander Gornikiewicz
    Department of Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
    Acta Biochim Pol 52:731-5. 2005
    ..However, while being selective for proliferating human endothelial cells, the recombinant retroviral particles displayed low transduction efficiencies and thus have to be further improved...
  73. ncbi Multidetector CT of pancreas: effects of contrast material flow rate and individualized scan delay on enhancement of pancreas and tumor contrast
    Gerd Schueller
    Department of Radiology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Radiology 241:441-8. 2006
    ....
  74. ncbi Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF
    Josef Friedl
    Surgical Metabolism Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 100:1334-9. 2002
    ..Rapid induction of TF by TNF may be the primary EC response that results in alterations in permeability and procoagulant activity observed following intravascular TNF administration in isolation perfusion...